ESMO 2018 Bladder Cancer

Viewing 1-12 of 12 articles

ESMO 2018: ABACUS, A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer

ESMO 2018: Overall Survival Results – RANGE, Ramucirumab and Docetaxel In Platinum-Refractory Urothelial Carcinoma

ESMO 2018: Comprehensive Biomarker Analyses and Updated Results of PURE-01 Study: Neoadjuvant Pembrolizumab in Muscle-Invasive Urothelial Bladder Carcinoma

ESMO 2018: Is There Still a Role for Chemotherapy in Bladder Cancer?

ESMO 2018: Neoadjuvant Therapy with Pembrolizumab Alone or in Combination with Cisplatin plus Gemcitabine for Locally Advanced Urothelial Cancer, A Phase Ib/2 Study

ESMO 2018: RANGE, A Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial of Ramucirumab and Docetaxel In Platinum-Refractory Urothelial Carcinoma: Overall Survival Results

ESMO 2018: A Phase Ib/2 Study of Neoadjuvant Pembrolizumab and Chemotherapy for Locally Advanced Urothelial Cancer

ESMO 2018: Nivolumab Alone or in Combination with Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma, including the Expansion from CheckMate 032

ESMO 2018: Invited Discussant - Nivolumab Alone or in Combination with Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma, from CheckMate 032

ESMO 2018: Nivolumab Alone or in Combination With Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma

ESMO 2018: Invited Discussant - Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to BCG: Phase 2 Keynote-057 Trial

ESMO 2018: Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG: Phase 2 Keynote-057 Trial

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.